Abbott Laboratories have gained huge profit after strong sales of generic drugs in emerging markets overseas, and it was on track to achieve its full-year earnings projections.
The North Chicago-based health care giant posted earnings of $580 million, or 38 cents a share, up from $538 million, or 36 cents a share, a year ago.
The company rang up worldwide sales of $5.15 billion, up 1.4 percent from a year ago. By division, the strongest sales growth was in generic drugs, up 24.6 percent, and the weakest was medical devices, down 7.4 percent.
Strong sales in China, India, Brazil and Russia helped Abbott reach its goals.
